Plain-English translation of NCT05065801 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new treatment approach for advanced pancreatic cancer works better than the current standard. Participants will be randomly assigned to receive either Gembrax (gemcitabine plus nab-paclitaxel) followed by Folfirinox, or Folfirinox alone. The goal is to see if the two-step approach helps people live longer and control their cancer better.
Pancreatic cancer is very serious and often diagnosed when it has already spread. While Folfirinox improved survival compared to older treatments, researchers want to see if starting with a different medication first and then switching to Folfirinox could work even better for patients.
You likely qualify if…
You likely don't qualify if…
If enrolled, you will be randomly placed into one of two groups. One group receives three rounds of Gembrax (given on specific days over 3 weeks, three times total), followed by two rounds of Folfirinox over the next 6 weeks. The other group receives four rounds of Folfirinox spread over about 6 weeks. Both groups will have blood tests and scans to monitor how the cancer responds and watch for side effects. The total treatment lasts up to 12 months in one group and 6 months in the other.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
France